Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by bit.bio

bit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox™ Cell Programming Technology
From bit.bio
Via Business Wire
bit.bio to Unveil iPSC Advancements and ioCells Toolkit at Society for Neuroscience 2024 Annual Conference
From bit.bio
Via Business Wire
bit.bio Expands Executive Team with Appointment of Przemek Obloj as Chief Financial Officer
From bit.bio
Via Business Wire
bit.bio Launches ioAstrocytes, Advancing How Scientists Can Model the Human Brain
From bit.bio
Via Business Wire
Nobel Laureate Thomas Südhof and bit.bio CEO Mark Kotter to Lead Fireside Chat on Programming Human Cells at SynBioBeta
From bit.bio
Via Business Wire
bit.bio Announces First Project Within Multi-Year Collaboration Agreement with The Michael J. Fox Foundation (MJFF) to Generate Human Cell Products for Research and Drug Discovery in Parkinson’s disease
From bit.bio
Via Business Wire
bit.bio Announced as Inaugural Partner of Ginkgo Bioworks’ New Technology Network
From bit.bio
Via Business Wire
Tickers DNA
bit.bio further expands ioCells™️ range with early access launch of ioMotor Neurons™️ for research and drug discovery in diseases such as amyotrophic lateral sclerosis (ALS)
From bit.bio
Via Business Wire
Scientists at King's College London and bit.bio Collaborate to Develop Multi-Cell Models of the Human Brain With Optimised Open-Source Protocols for Use by Any Researcher
From bit.bio
Via Business Wire
bit.bio Unveils Cell Therapy Pipeline, Including Lead Candidate for Acute Liver Failure, and Significantly Expands Scientific Advisory Board with Global Experts in Cell Therapy
From bit.bio
Via Business Wire
bit.bio introduces first product in groundbreaking ioCRISPR-Ready Cells™ product range, paving the way for new advances in disease modelling and drug discovery
From bit.bio
Via Business Wire
bit.bio is Industrialising Human Cell Manufacturing, Unleashing the Potential of Synthetic Biology for Reproducible Research and Affordable Regenerative Medicines
From bit.bio
Via Business Wire
bit.bio Launches New Custom Disease Model Cells Offering, Advancing Disease Research and Drug Discovery
From bit.bio
Via Business Wire
bit.bio Expands Board of Directors With Appointment of Distinguished Investor, Philanthropist, and Scientist
From bit.bio
Via Business Wire
bit.bio Expands Its Portfolio With Three New Human Cell Products for Research and Drug Discovery in Neurodegenerative and Neurological Diseases
From bit.bio
Via Business Wire
bit.bio Expands Independent Ethics and Sustainability Board as Part of Commitment to Being a Purpose Driven Company
From bit.bio
Via Business Wire
bit.bio Adds Two New Human Cell Products to Address the Translation Gap and Accelerate Research and Drug Discovery for Neurodegenerative Disease
From bit.bio
Via Business Wire
bit.bio named Emerging Star at European Mediscience Awards 2022
From bit.bio
Via Business Wire
bit.bio Presents Data at ISSCR Demonstrating Their Platform’s Capability to Create Any Human Cell
From bit.bio
Via Business Wire
bit.bio Celebrates Double Award Win at Cambridge Science and Technology Awards 2022 Including Biotech of the Year for the Second Time in a Row
From bit.bio
Via Business Wire
bit.bio’s New Huntington’s Disease Human Cell Model Set to Accelerate Drug Discovery and Screening
From bit.bio
Via Business Wire
Bit.bio Appoints Accomplished Biotechnology Executive and Drug Developer Kathryn Corzo as Chief Operating Officer
From Bit.bio
Via Business Wire
bit.bio Raises in Excess of $100 Million in First Close of Series B Financing
From bit.bio
Via Business Wire
bit.bio expands Board of Directors with the Appointment of Entrepreneurs and a Nobel Laureate
From bit.bio
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.